Comprehensive Guide to S-Adenosylmethionine (SAM)

S-Adenosylmethionine (SAM)Dr. James Meschino DC, MS, ND
Download in PDF format Download in Epub format Download in Kindle format
General Features
S-Adenosylmethionine (SAM) is an important methyl donor (CH3) in the transmethylation reactions required for the synthesis of DNA bases, creatine, glutathione, neurotransmitters (i.e. melatonin), phosphatidylcholine, and for liver detoxification reactions.
In the body, SAM is synthesized from methionine and ATP. Methionine, required for the synthesis of SAM, is obtained from diet, or produced from homocysteine, which accepts a methyl group (CH3) from vitamin B12; that was transferred to vitamin B12 from folic acid originally. Thus the synthesis of methionine and SAM are primarily dependant upon an adequate nutritional status of folic acid and vitamin B12.1,2,3
Curiously, high doses of methionine do not increase levels of SAM, but rather are associated with some degree of toxicity.4 The most natural way to optimize endogenous synthesis of S-Adenosylmethionine is to ensure adequate intake of folic acid, vitamin B12 and protein.3 Of clinical significance is the fact that SAM supplementation on its own has been shown to provide significant results in depression, osteoarthritis, fibromyalgia and liver disorders.
Clinical Application and Mechanism of Action
1. Depression, Anxiety and Dementia
As a principle donor of methyl groups (CH3) to various reactions, SAM is necessary for the synthesis of phospholipids (phosphatidylcholine, phosphatidylserine) and neurotransmitters. SAM supplementation in depressed or anxious patients has resulted in increased levels of serotonin, dopamine and phosphatidylserine. It improves binding of neurotransmitters to receptor sites, and affects brain cell membrane fluidity, resulting in significant clinical improvement in depression and anxiety.2,3,6,7,8 A number of excellent clinical trials have demonstrated the value of SAM as a natural biochemical intervention in depression. The typical dosage is 400 mg, three to four times per day (studies include general depression and post-partum depression).9-13
Alzheimer’s disease patients have been shown to have low levels of SAM and may therefore, benefit from its administration.2,3
2. Osteoarthritis
SAM has demonstrated impressive results in the treatment of osteoarthritis. SAM is required for the synthesis of cartilage components and appears to exert pain-relieving and anti-inflammatory properties.14,15 At least 21,524 patients with osteoarthritis have participated in clinical trials using SAM supplementation. Even when tested against commonly used anti-inflammatory drugs (i.e. Advil, Motrin, Nuprin, Naproxen) SAM supplementation has provided significant relief of osteoarthritic symptoms and improved joint function and quality of life. An MRI (magnetic resonance imaging) study demonstrated increased cartilage formation in 14 patients with osteoarthritis of the hands, given SAM vs. the placebo. Unlike non-steroidal anti-inflammatory drugs SAM is not harmful to the intestinal tract, kidney or liver. In fact, it is used to support liver detoxification functions in anti-aging and certain diseases.16-24 In the above studies, the typical dosage of SAM was 400 mg, three times per day.
3. Fibromyalgia
Several clinical studies show that SAM can help improve various aspects of fibromyalgia, including a reduction in the number of trigger points, painful areas and improvements in mood. Other symptoms that may respond to SAM supplementation include morning stiffness and fatigue. Treatment doses were in the range of 800 mg of SAM per day.25,26,27
4. Liver Disorders
SAM is beneficial for a variety of liver disorders because of its ability to promote bile flow and relieve cholestasis. It has been used successfully in cirrhosis, Gilbert’s Syndrome, and oral contraceptive induced liver damage. Its benefits are directly attributable to its role as a major methyl donor in the liver (detoxification process) and its lipotropic activity (transporting fat out of the liver). In Gilbert’s Syndrome SAM at a dosage of 400 mg, three times daily has resulted in a significant decrease in serum bilirubin. In liver cirrhosis it has been shown to improve cell membrane function, improve bile flow and increase levels of glutathione; possibly the most important liver antioxidant and detoxification agent. Animal studies provide evidence of protection against liver cancers from SAM supplementation in animals exposed to liver carcinogens.28-38
In alcoholic cirrhosis, damage to the liver prevents the natural formation of SAM from the amino acid methionine. In a double-blind study, individuals with alcoholic cirrhosis of the liver who took SAM supplementation for two years had a 47% lower rate of death or need for liver transplantation, compared with those receiving the placebo. In patients with less severe cirrhosis, the results were even more impressive.39
5. Migraine Headaches
A long-term study revealed that SAM supplementation may be helpful in reducing the incidence of migraines in sensitive individuals.
Dosage
For most conditions the therapeutic dosage range is typically 400 mg, two or three times daily. SAM can cause nausea and gastrointestinal disturbances in some people, thus, some patients may benefit from starting with 200 mg doses and working their way up to 400 mg per individual dose.5
1. Depression and Anxiety: 400 mg, three times per day
2. Osteoarthritis: 400 mg, two or three times per day
3. Fibromyalgia: 400 mg, two times per day
4. Liver Disorders: 400 mg, three times per day
5. Migraine Headache: 400 mg, two times per day (as a preventative intervention).
Adverse Side Effects, Toxicity and Contraindications
SAM should not be taken by individuals with bipolar (manic) depression, which may trigger a manic phase in these individuals. No other significant side effects have been reported with oral SAM supplementation other than occasional nausea and gastrointestinal disturbances
Drug-Nutrient Interactions
No known drug-nutrient interactions have been reported. However, as with folic acid, vitamin B12 and choline, SAM is a methyl donor, which may speed up the detoxification of various drugs in the liver.41 As well, SAM can affect neurotransmitter levels, caution should be exercised when using SAM in conjunction with anti-depressant and anti-anxiety medications. Excess serotonin production, for example, can lead to serotonin syndrome, characterized by myoclonus, rigidity, hyperreflexia, shivering, confusion, agitation, restlessness, coma, autonomic instability, low-grade fever, nausea, diarrhea, diaphoresis, flushing and rarely, rhabdomyloysis and death. This is true for all natural health products that can either increase the synthesis of serotonin or inhibit its degradation
References
1. Marks D, Marks A, Smith C, editors. Basic Medical Biochemistry: a Clinical Approach. Balitmore, MD: Williams & Wilkins. 1996. p. 614-21.
2. Healthnotes, Inc. 2001. www.healthnotes.com: SAMe.
3. Dietary Supplement Information Bureau. www.content.intramedicine.com: SAMe
4. Strementinoli G. Parmacological aspects of S-adenosylmethionine: pharmacokinetics and parmacodynamics. Am J Med 1987;83:35-42.
5. Murray M. Encyclopedia of Nutritional Supplements. Rocklin, CA: Prima Publishing; 1996. p. 365-73.
6. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987;83:95-103.
7. Reynolds E, Carney M, Toone B. Methylation and mood. Lancet 1983;ii:196-9.
8. Bottiglieri T, Laundry M, Martin R, et al. S-adenosylmethionine influences monoamine metabolism. Lancet 1984;ii:224.
9. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind placebo-controlled trial. Am J Psychiatry 1990;147:591-5.
10. Rosenbaum JF, Maurizio F, William E, et al. An open-label pilot study of oral S-adenosylmethionine in major depression. Psychopharmacol Bull 1988;24:189-94.
11. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992;52:478-85.
12. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993;59:34-40.
13. Cerutti R, Sichel MP, Perin M, et al. Psychological distress during puerperium: A novel therapeutic approach using S-adenosylmethionine. Curr Ther Res 1993;53:707–16.
14. Harmand M-F, Vilamitjana J, Maloche E, et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. Am J Med 1987;83:48-54.
15. Strementinoli G. Pharmacological aspects of S-adenosylmethionine: Pharmacokinetics and pharamcodynamics. Am J Med 1987;83:35-42.
16. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med 1987;83:81-3.
17. Glorioso S, Todesco S, Mazzi A, Marcolongo R, Giordano M, Colombo B, et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5:39-49.
18. Marcolongo R, Giordano N, Colombo B, et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Curr Ther Res 1985;37:82-94.
19. Domljan Z, Vrhovac B, Durrigl T, Pucar I. A double-blind trial of ademetionine vs Naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-33.
20. Caruso I, Peitrogrand V. Italian double-blind multicentre study comparing S-adenosylmethionine, Naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83:66-71.
21. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med 1987;83:78-80.
22. Maccagno A. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987;83:89-94.
23. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94.
24. Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis: report of an open phase IV study with ademetionine (Gumaral). Am J Med 1987;83:84-8.
25. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia: a double-blind crossover study. Am J Med 1987;83:107-10.
26. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991;20:294-302.
27. Di Benedetto P, Iona LG, Zidarich V. Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous nerve stimulation in primary fibromyalgia. Curr Ther Res 1993;53:222-9.
28. Mazzanti R, et al. On the antisteatosic effects of S-adenosyl-L-methionine in various chronic liver diseases: a multicentre study. Curr Ther Res 1979;25:25-32.
29. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo-controlled study. Gastroenterology 1990;99:211-5.
30. Adachi Y, et al. The effects of S-adenosyl-L-methionine on intrahepatic cholestasis. Jap Arch Int Med 1986;33:185-92.
31. Padova C, Tritapepe R, Padova F, et al. S-adenosyl-L-methionine antagonizes oral contraceptive-induced bile cholesterol supersaturation in healthy women: preliminary report of a controlled randomized trial. Am J Gastroenterol 1984;79:941-4.
32. Frezza M, Pozzato G, Chiesa L, Stramentinoli G, di Padova C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose s-adenosyl-L-methionine administration. Hepatol. 1984;4:274-278.
33. Frezza M, Pozzato G, Pison G, et al. S-adenosylmethionine counteracts oral contraceptive hepatotoxicity in women. Am J Med Sci 1987;293:234-8.
34. Bombardieri G, Milani A, Bernardi L, Rossi L. Effects of S-adenosyl-L-methionine (SAM) in the treatment of Gilbert’s syndrome. Curr Ther Res 1985;37:580-5.
35. Angelico M, Gandin C, Nistri A, Baiocchi L, Capocaccia L. Oral S-adenosyl-L-methionine (SAM) administration enhances bile salt conjunction with taurine in patient with liver cirrhosis. Scand J Clin Lab Invest 1994;54:459-64.
36. Kakimoto H, Kawata S, Imai Y, et al. Changes in lipid composition of erythrocyte membranes with administration of S-adenosyl-L-methionine in chronic liver disease. Gastroenterolia Japonica 1992;27:508-13.
37. Loguercio C, Nardi G, Argenzio F, Aurilio C, Petrone E, Grella A, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcoholism 1994;54:597-604.
38. Pascale RM, Marras V, Simile MM, Daino L, Pinna G, Bennati S, et al. Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res 1992;52:4979-86.
39. Mato JM, Cámara J, Fernández de Paz, Caballería L, Coll S, Caballero AM, et al. S-adenosyl-L-methionine in alcoholic liver cirrhosis: a randomized placebo-controlled, double-blind, multicentre clinical trial. J Hepatol 1999;30:1081-9.
40. Gatto G, Caleri D, Michelacci S, Sicuteri F. Analgesizing effect of a methyl donor (S-adenosylmethionine) in migraine: an open clinical trial. Int J Clin Pharmacol Res 1986;6:15-7.
41. Reicks M, Hathcock JN. Effects of methionine and other sulfur compounds on drug conjugations. Pharmac Ther 1998;37:67-79.
42. Bodner RA, Lynch T, Lewiss L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23.
43. Bressa GM. S-adenosylmethionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994;154:7-14.